Tag:

Generics

Latest Headlines

Latest Headlines

Diovan generic floodgates open with FDA nods for Mylan, et al.

Novartis took its first big hit from new Diovan generics during last year's third quarter, when Ranbaxy Laboratories finally won approval for its exclusive generic of the blood pressure pill. And it was indeed a big hit: a 76% drop in U.S. sales for the franchise, to $97 million.

Sanofi strikes out in bid to escape France's $49M Plavix antitrust fine

No luck for Sanofi in turning over a Plavix antitrust fine. A Paris appeals court has upheld the €40.6 million ($49.7 million) penalty for trying to keep doctors and pharmacists from prescribing or subbing copycat versions of the former blockbuster blood thinner,  Law360  reports.

Mylan, Actavis prevail in Celebrex exclusivity fight, pushing Teva aside

Not so fast, Teva. The generics giant--which last week said it was set to roll out copies of Pfizer blockbuster Celebrex--now has to put those plans on hold, as per a U.S. appeals court ruling.

Bayer fails last-ditch attempt to block India's cheap Nexavar copies

Bayer was dealt a crushing blow in its ongoing fight to block generic sales of its cancer powerhouse Nexavar in India, as the country's Supreme Court ruled that an Indian generics group had the right to sell a copycat version of the drug.

To substitute or not to substitute? Biotechs and biosim makers compromise on legislation

Biotech companies and biosimilars makers have been squabbling for years about the way the lower-cost copies will be prescribed and distributed. Brand makers wanted to raise hurdles to replacing their meds with biosimilar versions. But now, with biosimilars nearing their U.S. debut, the two sides have reached a compromise.

Another Pfizer blockbuster bites the dust as Celebrex generics roll

Look out, Pfizer--the generics are here. On Wednesday, Teva and Mylan both launched versions of the company's arthritis med Celebrex, meaning Pfizer is about to watch the sales decline of yet another blockbuster.

AbbVie's Humira competition begins with Cadila's biosimilar launch in India

Indian drugmaker Zydus Cadila has launched a biosimilar of Humira in its home market--the first in a long line of in-development copies to threaten AbbVie's powerhouse med.

AstraZeneca scores a victory in pay-for-delay Nexium case

Last year, the U.S. Supreme Court slapped the industry with an unfavorable pay-for-delay verdict, ruling that consumers have the right to challenge brand-name drugmakers' patent settlements with generics companies. Now, in what could become a bellwether case for the industry, AstraZeneca scored a victory federal court as a jury found that the company's deal with Ranbaxy Laboratories to delay a generic launch of its heartburn med Nexium was not anticompetitive.   

Epirus and Ranbaxy launch a Remicade biosimilar in India

The biosimilar bonanza is underway, and Johnson & Johnson's rheumatoid arthritis drug Remicade is at the center of the copycat action. Boston-based biosimilar maker Epirus Biopharmaceuticals is rolling out a knockoff of the monoclonal antibody (mAb) in India with partner Ranbaxy Laboratories, a year after Hospira got its Remicade version approved in Europe.

Ranbaxy sues FDA to protect its exclusive for generic Nexium

Ranbaxy Laboratories has filed a federal lawsuit trying to reverse the FDA's decision to cancel its approvals to make generics of AstraZeneca's blockbuster Nexium and Roche's Valcyte.